Xu Yang

机构：High Throughput Biology (United States) · ORCID：0009-0006-9043-8162

发表论文 27 篇 · 总被引 136 次 · h-index 7

代表论文

• Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study (2023 · Cancer Immunology Immunotherapy · 被引 34)
• High incidence combination of multiple primary malignant tumors of the digestive system (2022 · World Journal of Gastroenterology · 被引 29)
• Metabolic Tumor Volume Measured by 18F-FDG PET/CT is Associated with the Survival of Unresectable Hepatocellular Carcinoma Treated with PD-1/PD-L1 Inhibitors Plus Molecular Targeted Agents (2023 · Journal of Hepatocellular Carcinoma · 被引 15)
• Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC (2023 · Frontiers in Immunology · 被引 12)
• Radiation Dose–Volume Effects on Negative Tumor-Draining Lymph Nodes Affected T-cell Activation and Prognosis in Esophageal Cancer with Chemoradiotherapy (2025 · Clinical Cancer Research · 被引 8)
• Application of four-dimensional cone beam computed tomography in lung cancer radiotherapy (2023 · Radiation Oncology · 被引 7)